[Molecular mechanisms of the therapeutic agents for kidney diseases: Anti-platelets/anti-coagulant medicines].
Maruyama
Ikuro
I
Laboratory and Vascular Medicine, Cardiovascular and Respiratory Disorders, Advanced Therapeutics, Kagoshima University, Graduate School of Medical and Dental Sciences.
D000925:Anticoagulants / Q000627:therapeutic use*; D004176:Dipyridamole / Q000627:therapeutic use; D005337:Fibrin / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology*; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D044463:Receptor, PAR-1 / Q000502:physiology; D044464:Receptor, PAR-2 / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D014859:Warfarin; D004176:Dipyridamole; D005337:Fibrin